CLNN Clene Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1822791 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-47.7%
TTM net income YoY20.4%
TTM EPS YoY—
Revenue 3-yr CAGR-22.1%
Net income 3-yr CAGR—
Margins
Gross margin79.5%
Operating margin-9,676.3%
Net margin-11,520.5%
FCF margin-6,240.1%
EBITDA margin-9,195.3%
Returns
ROE-1,738.4%
ROA-98.9%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets132.4%
Debt / equity—
Current ratio1.57x
Interest coverage-8.14x
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio-45.4%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $200,000 | $342,000 |
| Cost of revenue | $43,000 | $70,000 |
| Gross profit | $157,000 | $272,000 |
| R&D expense | $14.01M | $20.06M |
| SG&A expense | $9.23M | $13.31M |
| Operating income | -$23.08M | -$33.09M |
| Interest expense | $2.68M | $4.06M |
| Pretax income | -$26.17M | -$39.40M |
| Income tax | $0 | $0 |
| Net income | -$26.17M | -$39.40M |
| EBITDA | -$21.59M | -$31.45M |
| EPS (basic) | -2.65 | -5.67 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $5.19M | $12.15M |
| Short-term investments | — | $0 |
| Receivables | $0 | $64,000 |
| Inventory | $37,000 | $68,000 |
| Current assets | $8.98M | $16.16M |
| PP&E, net | $6.02M | $7.48M |
| Total assets | $18.13M | $27.34M |
| Current liabilities | $10.78M | $10.29M |
| Long-term debt | $17.79M | — |
| Total debt | $17.79M | — |
| Total liabilities | $35.72M | $36.19M |
| Shareholders' equity | -$17.59M | -$8.86M |
| Net debt | $12.60M | — |
| Shares outstanding | 10.85M | 8.09M |
| Cash flow statement | ||
| Operating cash flow | -$18.55M | -$21.33M |
| Capital expenditure | $39,000 | $15,000 |
| Free cash flow | -$18.59M | -$21.34M |
| Investing cash flow | -$39,000 | $6.32M |
| Financing cash flow | $11.52M | -$1.53M |
| Depreciation & amortization | $1.50M | $1.65M |
| Stock-based compensation | $6.38M | $7.95M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.